India · Delayed Price · Currency is INR Emcure Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
FY 2026 saw 16.6% revenue growth, 41% adjusted PAT growth, and margin expansion, driven by strong international and resilient domestic performance. FY 2027 guidance is for low-to-mid-teen revenue growth and further margin gains, with Zuventus integration stabilizing.
-
Q3 FY26 saw 20.4% revenue growth and 48% PAT growth, driven by strong domestic and international performance, new launches, and margin expansion. Strategic partnerships, innovation, and government support for biologics position the company for sustained double-digit growth and margin improvement.
-
Q2 FY2026 saw 13% revenue growth and record profits, driven by strong domestic and international performance. Strategic moves included a Novo Nordisk partnership for Semaglutide and full Zuventus acquisition, with margin and debt targets updated following recent M&A.
-
Q1 FY2026 delivered strong growth with revenue up 15.7% and profit after tax up 41% year-over-year. Domestic and international segments both outperformed, with new product launches and partnerships driving momentum. EBITDA margin improved to 19.2%.
Fiscal Year 2025
-
FY 2025 saw 19% revenue growth and 34% PAT increase, driven by strong domestic and international performance, portfolio expansion, and successful integration of acquisitions. FY 2026 guidance targets 13-14% revenue growth, 150 bps margin improvement, and further debt reduction.
-
Q3 FY25 revenue grew 18% YoY, with strong international and emerging market performance, but gross margins declined due to business mix. Margin improvement and growth are expected from new launches in derma, ophthalmology, and productivity gains, with net debt targeted to be eliminated by March 2026.